The main department of described VC is located in the Cambridge. The fund was located in North America if to be more exact in United States.
The important activity for fund was in 2016. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. Opposing the other organizations, this WuXi Healthcare Ventures works on 15 percentage points less the average amount of lead investments. The real fund results show that this VC is 2 percentage points less often commits exit comparing to other companies. When the investment is from WuXi Healthcare Ventures the average startup value is 500 millions - 1 billion dollars. The increased amount of exits for fund were in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars.
The overall number of key employees were 2.
The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. We can highlight the next thriving fund investment areas, such as Medical, Genetics. Among the most popular portfolio startups of the fund, we may highlight 23andMe, CStone Pharmaceuticals, Hua Medicine. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the WuXi Healthcare Ventures, startups are often financed by ARCH Venture Partners, Avalon Ventures, Torrey Pines Investment. The meaningful sponsors for the fund in investment in the same round are F-Prime Capital, ARCH Venture Partners, Canaan Partners. In the next rounds fund is usually obtained by Venrock, ARCH Venture Partners, 6 Dimensions Capital.
Related Funds
Funds with similar focus
Fund Name | Location |
Avataar Venture Partners | Bangalore, India, Karnataka |
Black Coral Capital | Boston, Massachusetts, United States |
Blackbird Ventures | - |
Canyon Creek Capital | California, Santa Monica, United States |
Franchise India Holdings Limited | Delhi, India, New Delhi |
Georgian Co-Investment Fund | Georgia, Tbilisi, Tbilisi |
Gilde Healthcare | The Netherlands, Utrecht, Utrecht |
Global Frontier Partners | Bangalore, India, Karnataka |
Guloien Capital | - |
Hangzhou Binjiang Real Estate Group | China, Hangzhou, Zhejiang |
HIX Capital | Brazil, São Paulo, Sao Paulo |
Huidaya Investment Management | China, Hubei, Wuhan |
Kearny Bank | - |
MarathonArtists LABs | England, London, United Kingdom |
New York Ventures | New York, New York, United States |
QuaeroQ | - |
SODECI | Abidjan, Côte d'Ivoire, Lagunes |
Stirling Square Capital Partners | Kersey, Lancashire, United Kingdom |
Sunwoda Electronic | China, Guangdong, Shenzhen |
Susquehanna | Lititz, Pennsylvania, United States |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Zenas BioPharma | 23 Mar 2021 | - | |||
LifeMine Therapeutics | $50M | 07 Jan 2021 | Cambridge, Massachusetts, United States | ||
Halda Therapeutics | $25M | 13 Nov 2020 | Branford, Connecticut, United States | ||
XW Laboratories | $40M | 18 Sep 2020 | Jiang'an District, Hubei, China | ||
Antengene Corporation | $120M | 02 Jan 2019 | Shanghai, China | ||
Refuge Biotechnologies | $25M | 02 May 2018 | California, United States | ||
UNITY Biotechnology | $55M | 19 Mar 2018 | California, United States | ||
IDEAYA Biosciences | $94M | 15 Mar 2018 | South San Francisco, California, United States | ||
Medeor Therapeutics | $57M | 27 Nov 2017 | South San Francisco, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Zenas BioPharma | 23 Mar 2021 | - | |||
LifeMine Therapeutics | $50M | 07 Jan 2021 | Cambridge, Massachusetts, United States | ||
Halda Therapeutics | $25M | 13 Nov 2020 | Branford, Connecticut, United States | ||
XW Laboratories | $40M | 18 Sep 2020 | Jiang'an District, Hubei, China | ||
Antengene Corporation | $120M | 02 Jan 2019 | Shanghai, China | ||
Refuge Biotechnologies | $25M | 02 May 2018 | California, United States | ||
UNITY Biotechnology | $55M | 19 Mar 2018 | California, United States | ||
IDEAYA Biosciences | $94M | 15 Mar 2018 | South San Francisco, California, United States | ||
Medeor Therapeutics | $57M | 27 Nov 2017 | South San Francisco, California, United States |